Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02125539 · ClinicalTrials.gov registry record · Phase 2
Field Trial of a Relapse Prevention Program for Adolescents Receiving Substance Use Treatment
A Phase 2 study, sponsored by Inflexxion.
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT02125539: Completed Phase 2 study, sponsored by Inflexxion.
NCT02125539 is a Phase 2 study that has completed, run by Inflexxion. The registered enrollment target is 160 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02125539, a Phase 2 study, has completed, sponsored by Inflexxion.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
The purpose of this study is to provide a comprehensive evaluation of the new, Navigating my Journey program for adolescents receiving treatment in an outpatient substance abuse center. The primary hypotheses are that, relative to the control condition, Navigating my Journey will be associated with significantly higher motivation, higher self-efficacy, improved relapse coping skills, and lower substance use. The secondary hypotheses are that, relative to the control condition, Navigating my Journey will be associated with increased therapeutic alliances with counselors.
Primary Outcome
Participants will be asked how many days in the past 30 days they used a variety of substances, including alcohol. This self report question format is widely used to assess substance use (e.g., the GPRA from CSAT; SAMHSA, 2010).
Interventions
- BEHAVIORAL Attention Control
- BEHAVIORAL Navigating my Journey program
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
What the finished NCT02125539 record still lists
NCT02125539 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% higher).
The record links to 0 conditions, and to 2 interventions - of which Attention Control is the first listed.
NCT02125539 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02125539 about?
NCT02125539 is a clinical study titled "Field Trial of a Relapse Prevention Program for Adolescents Receiving Substance Use Treatment". The purpose of this study is to provide a comprehensive evaluation of the new, Navigating my Journey program for adolescents receiving treatment in an outpatient substance abuse center. The primary hypotheses are that, relative to the control condition, Navigating my Journey will be associated with...
What is the current status of trial NCT02125539?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2014-09. Estimated completion is 2015-06.
What interventions are being tested in trial NCT02125539?
The interventions under investigation include: Attention Control (BEHAVIORAL), Navigating my Journey program (BEHAVIORAL).
Who is sponsoring clinical trial NCT02125539?
This trial is sponsored by Inflexxion, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02125539's enrollment target sits among peer trials
160 422nd of 2000 higher than 1,559 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia